Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.

J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23.

2.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
3.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
4.

Targeting the mTOR signaling pathway in neuroendocrine tumors.

Chan J, Kulke M.

Curr Treat Options Oncol. 2014 Sep;15(3):365-79. doi: 10.1007/s11864-014-0294-4. Review.

5.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Review.

PMID:
21932937
6.

Systemic therapy for advanced pancreatic neuroendocrine tumors.

Kulke MH.

Semin Oncol. 2013 Feb;40(1):75-83. doi: 10.1053/j.seminoncol.2012.11.010. Review.

7.

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F.

Cancer Res. 2013 Mar 1;73(5):1449-53. doi: 10.1158/0008-5472.CAN-12-3923. Epub 2013 Feb 22. Review.

8.

Pancreatic NETs: where do we stand now?

Faivre S, Castellano D, Strosberg J, González E, Salazar R.

Cancer Metastasis Rev. 2014 Mar;33(1):361-6. doi: 10.1007/s10555-013-9466-0. Review.

PMID:
24452757
9.
10.

Novel agents in gastroenteropancreatic neuroendocrine tumors.

Stevenson R, Libutti SK, Saif MW.

JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. Review.

11.

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P, Hentic O.

Bull Cancer. 2014 Feb;101(2):175-83. doi: 10.1684/bdc.2014.1887. Review. French.

PMID:
24557872
12.

Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.

Miljković MD, Girotra M, Abraham RR, Erlich RB.

Dig Dis Sci. 2012 Jan;57(1):9-18. doi: 10.1007/s10620-011-1854-0. Epub 2011 Sep 22. Review.

PMID:
21938486
13.

Pancreatic neuroendocrine neoplasms.

Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Review.

PMID:
23207615
14.

Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.

Abdel-Rahman O, Fouad M.

Tumour Biol. 2015 Feb;36(2):467-78. doi: 10.1007/s13277-015-3064-4. Epub 2015 Jan 18. Review.

PMID:
25596701
15.

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.

Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A.

Ann Oncol. 2014 Apr;25(4):763-73. doi: 10.1093/annonc/mdu021. Review.

16.

[Drug therapy for neuroendocrine tumours].

Tóth M.

Orv Hetil. 2013 Sep 29;154(39):1556-64. doi: 10.1556/OH.2013.29718. Review. Hungarian.

PMID:
24058101
17.

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D.

World J Gastroenterol. 2015 Feb 14;21(6):1945-55. doi: 10.3748/wjg.v21.i6.1945. Review.

18.

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS.

World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. Review.

19.

Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.

Abdel-Rahman O, Fouad M.

Future Oncol. 2015;11(8):1275-90. doi: 10.2217/fon.14.302. Review.

PMID:
25832882
20.

Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.

Khagi S, Saif MW.

Curr Opin Oncol. 2015 Jan;27(1):38-43. doi: 10.1097/CCO.0000000000000146. Review.

PMID:
25390554
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk